Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)

Article Oncology

The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL

Seval Akpinar et al.

Summary: In this study, we evaluated the safety and efficacy of single-agent ibrutinib for relapsed/refractory CLL in real-world settings. The results demonstrated good safety and efficacy, with a median overall survival of 52 months.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

Add to Collection

Article Oncology

Results of a Prospective Non-Interventional Post-Authorization Safety Study of Idelalisib in Germany

Manuela A. Hoechstetter et al.

Summary: This real-world study demonstrates the robust effectiveness and manageable safety of Idelalisib in patients with chronic lymphocytic leukemia and relapsed follicular lymphoma in Germany. The results are consistent with the effectiveness and tolerability profile observed in clinical trials.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

Add to Collection

Article Hematology

Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials

Max J. Gordon et al.

Summary: Comorbidities do not significantly impact outcomes in CLL patients treated with idelalisib. In patients with high comorbidities or severe comorbidities, idelalisib + anti-CD20 combination therapy is associated with superior PFS and ORR compared to anti-CD20 monotherapy.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Article Oncology

Chronic lymohocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

B. Eichhorst et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Hematology

Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases

Fortunato Morabito et al.

Summary: The study compared the effectiveness of IB and IDELA-R in prolonging overall survival in CLL patients, with results indicating a superior protective effect of IB over IDELA-R. Despite some limitations, these observations could provide valuable insights for clinical practice.

EUROPEAN JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Article Oncology

Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group

Gian Matteo Rigolin et al.

Summary: In a real-life analysis of 149 patients with relapsed/refractory chronic lymphocytic leukemia, the efficacy of idelalisib and rituximab (IR) showed longer progression-free survival at experienced centers, with performance status and number of previous therapy lines being strong prognostic factors.

HEMATOLOGICAL ONCOLOGY (2021)

Add to Collection

Article Hematology

A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel)

Toby A. Eyre et al.

Summary: The study examined the efficacy and safety of IDL-R treatment in 110 CLL patients and found clear efficacy in routine practice without identifying new safety signals. Careful management of known toxicities is crucial during treatment.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Editorial Material Hematology

Searching for a home: phosphoinositide 3-kinase inhibitors for chronic lymphocytic leukaemia in modern clinical practice

Lindsey E. Roeker et al.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Article Hematology

Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?

Alessandra Tedeschi et al.

Summary: Functional reserve of organs and systems plays a crucial role in predicting immunochemotherapy tolerance. Factors like age, comorbidities, and performance status are important in determining treatment feasibility and outcomes in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib. While age-related conditions may impact drug management, baseline ECOG-PS and neutropenia are the most accurate predictors of treatment feasibility and outcomes in this patient population.

BLOOD ADVANCES (2021)

Add to Collection

Article Oncology